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The expression of tumour suppressors and
proto-oncogenes in tissues susceptible to
their hereditary cancers
Brian Muir*,1 and Leonard Nunney1
1Department of Biology, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA
Background: Studies of familial cancers have found that only a small subset of tissues are affected by inherited mutations in a
given tumour suppressor gene (TSG) or proto-oncogene (POG), even though the mutation is present in all tissues. Previous tests
have shown that tissue specificity is not due to the presence vs absence of gene expression, as TSGs and POGs are expressed in
nearly every type of normal human tissue. Using published microarray expression data we tested the related hypothesis that
tissue-specific expression of a TSG or POG is highest in tissue where it is of oncogenic importance.
Methods: We tested this hypothesis by examining whether individual TSGs and POGs had higher expression in the normal
(noncancerous) tissues where they are implicated in familial cancers relative to those tissues where they are not. We examined
data for 15 TSGs and 8 POGs implicated in familial cancer across 12 human tissue types.
Results: We found a significant difference between expression levels in susceptible vs nonsusceptible tissues. It was found that
9 (60%, Po0.001) of the TSGs and 5 (63%, Po0.001) of the POGs had their highest expression level in the tissue type susceptible to
their oncogenic effect.
Conclusions: This highly significant association supports the hypothesis that mutation of a specific TSG or POG is likely to be most
oncogenic in the tissue where the gene has its highest level of expression. This suggests that high expression in normal tissues is a
potential marker for linking cancer-related genes with their susceptible tissues.
The tissue specificity of an inherited predisposition to cancer has
been known of and speculated upon for a long time (Morgan, 1922;
Little, 1923). It is a pattern seen in both tumour suppressor genes
(TSGs) and proto-oncogenes (POGs). For example, inherited
mutations in the TSG BRCA1 severely increase the risk of cancer in
breast and ovarian tissues, but cause no added risk of cancer in
many other tissue types (Welcsh and King, 2001). Similarly,
inherited mutations in the KIT POG specifically increase the risk of
gastrointestinal stromal tumours (Lindor et al, 2008).
Attempts to explain these phenomena have largely focussed on
TSGs (Bignold, 2004), with the usual assumption being that a given
TSG acts as a critical cancer suppressor in the predisposed tissues,
but not in those tissues with no elevated risk of hereditary cancer
(Weinberg, 1988; Horowitz et al, 1990). For example, Weinberg
(1988; Horowitz et al, 1990) proposed that RB1 had been recruited by
evolutionary processes for the regulation of cell division in retinal and
bone tissues, given that RB1 germline mutations were associated with
high lifetime risks of retinoblastoma (Knudson, 1971) and osteosar-
coma (Stratton et al, 1989).
This explanation of tissue specificity was formalised into an
evolutionary model of cancer suppression by Nunney (1999).
The model is based on multistage carcinogenesis and quantifies
how cancer risk increases with a larger body size (more cells) and
a longer lifespan (more cell divisions) (a relationship strongly
supported by data from humans and dogs; Nunney, 2013), and
how increased pre-reproductive risk drives natural selection for
tissue-specific increases in cancer suppression. This recognition
that cancer suppression is an evolving trait resolves the paradox
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first noted by Peto (1977): why don’t large long-lived humans have
much higher rates of cancer than small short-lived mice?
This suppression is predicted to involve either tissue-specific
mechanisms that directly reduce the risk of the target cancer
(e.g., a TSG upregulated in a single tissue) or more general
mechanisms affecting all tissues that would also lower the risk of all
cancers. Examples of general mechanisms (global telomerase
suppression, and early contact inhibition) have already been
identified in large and long-lived rodents (Seluanov et al, 2007, 2009).
Tissue-specific mechanisms are harder to detect, but the
serendipitous availability of tissue-specific mutations would predict
that different TSGs may be recruited independently over time in
different tissues within a species, and that different TSGs may be
recruited in the same tissue in different species clades.
One potential consequence of this evolutionary process would
be that TSGs are only expressed in tissues where they actively
suppress carcinogenesis. However, most TSGs and POGs are
expressed in every type of normal human tissue. This was first
investigated using RB1 that was found to be expressed in every
tissue tested (Friend et al, 1986; Fung et al, 1987; Lee et al, 1988).
Studies of other genes have found the same pattern in gene
expression (Fearon, 1997; Vogelstein and Kinzler, 2004) and
protein data (Plevova´ et al, 2005).
The ubiquitous expression of TSGs and POGs has thus been
recognised as an enigma of cancer research (Knudson, 1989;
Weinberg, 1989, 2007; Eng and Ponder, 1993; Brown and
Solomon, 1997; Fearon, 1997; Bignold, 2004; Vogelstein and
Kinzler; 2004), prompting alternative explanations that do not
predict differences in expression across tissue types (see Bignold,
2004; Friedenson, 2010). For example, it has been proposed that
the specificity of BRCA1 to breast and ovarian cancers might result
from BRCA1 mutations being less likely to induce apoptosis in
breast and ovarian tissues than in other tissues (Elledge and Amon,
2002, see also Monteiro, 2003). However, such ad hoc hypotheses
lack generality because they fail to explain why such tissue
specificity is the rule rather than the exception.
Recent work on TSGs suggests that their level of expression,
rather than presence or absence, may be an important indicator of
the cancer suppressing activity. The TSGs have multiple functions
affecting tissues generally, in addition to their roles in cancer
suppression (Venkitaraman, 2002; Silver and Livingston, 2012);
however, a higher tissue-specific level of expression may indicate a
role in suppressing cancer in the target tissue. Berger et al (2011)
recently argued that higher levels of TSG expression correspond to
lower cancer risk. For example, mice with slightly reduced
expression levels (80%) of the TSG Pten have intermediate
mammary tumour incidence compared with Ptenþ /þ (100%)
and Ptenþ / (50%) mice (Alimonti et al, 2010). In humans,
haploinsufficiency of the TSGs PTEN (Marsh et al, 1998) and TP53
(Varley et al, 1997) has been linked to cancer, and this runs
counter to the expectation that a single copy of a TSG is sufficient
to suppress cancer. In such cases, loss-of-heterozygosity events of
the remaining wild-type allele were not found. This suggests that,
at least in some cases, a 50% reduction in expression substantially
reduces the protective effect of a TSG.
Overall, these findings suggest that TSGs may be expressed at
constitutively higher levels in the tissues where they are recruited
to suppress cancer relative to those in which they are not. This
hypothesis has been tested by two studies to date; however, support
was weak or absent. Plevova´ et al (2005) examined the protein
expression levels of the DNA mismatch repair tumour suppressors,
MLH1 and MSH2, commonly associated with colorectal and
uterine cancers. They found that both proteins had significantly
higher expression in the susceptible tissues, but only if non-
susceptible testes tissue that showed the highest expression level for
both proteins was excluded. Lage et al (2008) used microarray data
from noncancerous samples of 73 tissues to examine the relative
expression of 51 genes linked to hereditary cancer and did not find
the predicted pattern in POGs or TSGs.
The two-hit role of TSGs in cancer suppression is well
established; however, it is also possible for POGs to be recruited
to provide one-hit protection (Nunney, 1999). The role of POGs in
transmitting growth signals (Bunz, 2008) appears to make them
less likely candidates for cancer suppression, as it requires that each
added POG defines a new necessary signal for tissue growth.
However, POGs are implicated in some familial cancers (the first
was RET; Mulligan et al, 1993) and their possible role in the
evolution of cancer suppression needs to be investigated. To this
end, we were interested in testing the same hypothesis in POGs
that has been proposed for TSGs: that a POG has higher expression
in the susceptible tissue type(s) assuming that a susceptible tissue is
where the POG provides a required signal for tissue growth.
The goal of this study was to test the prediction that TSGs and
POGs implicated in familial cancer in a specific tissue are expected
to have a high level of expression in that tissue. Using 15 TSGs and
8 POGs implicated in various tissue-specific familial cancers, we
tested for higher expression in the affected tissue across 12 tissue
types (plus some additional subtypes) using published mRNA
expression data from normal (noncancerous) tissues.
MATERIALS AND METHODS
Gene expression data set. We used data from 35 independently
published microarray data sets documenting gene expression for a
range of human tissues (see Table 1 and Supplementary Table 1)
using the HG-U133A Affymetrix (Santa Clara, CA, USA) platform.
These data were compiled and normalised by Zheng-Bradley et al
(2010), and the data set is publicly available online at ArrayExpress
(Accession no. E-MATB-27). The multistudy data set was down-
loaded using the Bioconductor software (Gentleman et al, 2004) in
R (R Development Core Team, 2008). All probe sets were retained
in our subset. Most cancer-related genes were covered by a single
probe set. In those cases where two probe sets were present
(RB1 and PTCH1), these were included as replicate measures of
expression.
In our analysis we used all of the broad tissue categories used
to group the biological samples in the data set except for cell line
and liver, because cell line samples may not accurately reflect
expression at the tissue level in vivo, and the liver tissue category
contained only a single sample. We also removed tissues annotated
as ‘disease’ or ‘neoplasia’ as only normal tissue was being analysed.
The final 12 tissue categories used in the analysis and their
corresponding sample sizes are represented in Table 1.
Criteria for selecting genes. Our initial screen required that
a TSG or POG could be included in the analysis only if it was
implicated in cancer via both germline and somatic mutations
(using Supplementary Table S1 in Futreal et al, 2004). Both types of
mutational effect were included in the screen in order to select only
those TSGs and POGs likely to increase susceptibility across
a range of developmental conditions in which the genes are
mutated. For example, if a gene had a germline effect, but no
known somatic effect, then this could indicate that the oncogenic
activity of the mutant gene was restricted to very early
development, a possibility our analysis of adult tissue could not
detect.
In our second screen, we identified tissues significantly at risk
from germline mutation using the criterion that lifetime cancer risk
(by age 70 years) for individuals carrying a mutation in the target
gene had to be Z25% using median values from Lindor et al
(2008). When relative risk (RR) scores were reported, the RR was
converted using baseline risk data (x) from Surveillance
Epidemiology and End Results (SEER) (Ries et al, 2008), that is,
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(x)(RR)Z25. For some genes, the 25% criterion excluded all tissue
types. For these genes alone, a single tissue type that most exceeded
a lower threshold of 15% lifetime risk was retained.
In applying this second screen it was found that of the POGs
identified in the first screen, only RET (multiple endocrine
neoplasia type II), HRAS, and KIT were included in Lindor et al
(2008). RET passed the second screen. However, as the absence of
the other POGs was probably because of their relatively recent
discovery as hereditary cancer genes, we used other sources to
assess risk. Each one of these genes was associated with only one
major cancer type, as reported in the Cancer Gene Census (Futreal
et al, 2004; Supplementary Table S1), and all of these cancer types
were found to be above the 25% lifetime risk threshold using data
from OMIM (Online Mendelian Inheritance in Man; see Hamosh
et al, 2005).
Cancers affecting a tissue not represented in the 12 tissue types
were not considered (e.g., colorectal cancer). Also excluded were
(1) cancer types with diverse tissues of origin such as harmartomas
and desmoid tumours, and (2) cancer types with unknown tissues
of origin, such as rhabdoid tumours.
Statistical tests. All statistical tests were performed in the
statistical program R (R Development Core Team, 2008), with
the exception of the nested ANOVA model for which Minitab 16
(Minitab Inc., Pennsylvania, PA, USA) was used. The normality
and equal variance assumptions of the log2(expression) data for
each gene were tested using the Jarque–Bera test and the Bartlett
test. As the data for several genes were found to be nonnormal, in
most cases nonparametric statistical tests were performed.
Tissue and subtissue categories. All statistical testing for higher
expression in susceptible tissues relative to nonsusceptible tissues
were performed initially using the 12 broad tissue categories with
(usually) one tissue identified as ‘susceptible’ for each gene and the
remainder grouped as ‘nonsusceptible’. For some genes it was
possible to use subtissue data (given an adequate sample size 42;
see Table 1) to refine the initial analysis by identifying the
susceptible subtissue within the susceptible tissue using OMIM
(Hamosh et al, 2005), so that the remaining subtissue samples of
that tissue type could be grouped as ‘nonsusceptible subtissues’,
creating a 13th category.
Comparing gene expression in susceptible vs nonsusceptible
tissue groups. The grand mean expression values of each gene in its
susceptible vs nonsusceptible tissues/subtissues were compared using
the one-tailed Wilcoxon signed rank test applied separately to TSGs
and POGs. The one-tailed test was performed, given the directional
alternate hypothesis of higher expression in susceptible tissue. For
each gene, the grand means were calculated as the unweighted
average of the means of the relevant tissue/subtissue groups.
In a second analysis, each gene was tested individually. First, for
each gene, we tested for significant differences in expression levels
among the tissue/subtissue groups using the Kruskal–Wallis test. If
significant expression-level differences between tissues were
established (Po0.05 after Bonferroni correction for testing
multiple genes), the Kruskal–Wallis multiple comparison test was
performed across the tissue types. In this a posteriori test, which
controlled the family-wise error rate at 0.05, the tissue means were
ranked and grouped by significance, with the ‘A’ group
corresponding to the highest expression level. Tissues could be
assigned to more than one group, for example, expression in a
tissue classified as ‘AB’ would only be significantly higher than
tissues not in groups ‘A’ or ‘B’. Only those tissue types marked as
‘A’ alone (i.e., not ‘AB’ etc.) were considered most highly expressed
(see Figure 1).
The number of ‘A’ classifications assigned to the susceptible
tissue/subtissue of TSGs or POGs relative to the total number of
‘A’ classifications was used to determine whether there was a
Table 1. The 12 broad tissue categories and the 38 subtissue
types contained in the analysed multistudy data set that was
compiled from 35 independent studies
Tissue category
Sample
size
Original data
source
Adipocyte 14 1, 2
Adipose tissue normal 8
Adipose-derived adult stem cells 6
Bone 7 3
Bone 7
Brainþ nerve 150 4, 5, 6, 7, 8, 9
Amygdala 1
Brain 39
Caudate nucleus 30
Cerebellum 26
Frontal cortex 27
Hippocampus CA1 5
Hypothalamus 20
Prefrontal cortex 2
Endocrine organs 7 7, 10
Thyrocyte 6
Thyroid gland 1
Epithelium 33 11
Bronchial epithelium 33
Gastrointestinal organs 13 12, 13
Oesophagus epithelium 7
Small intestines 6
Headþneck 33 14, 15, 16, 17, 18
Conjuctiva 4
Hypopharynx 3
Oropharynx 1
T cell 9
Tonsil 10
Trabecular meshwork cell 6
Heartþmuscle 74 19, 20, 21, 22,23, 24,
25, 26
Heart 36
Myometrium 12
Skeletal muscle 17
Smooth muscle 9
Immune system 25 15, 27, 28
CD34þ blood cell thymus 1
Lymph node 10
Thymocyte 14
Female reproductive 34 26, 29, 30, 31
Ovary 4
Placenta basal plate 21
Smooth muscle 1
Theca 8
Male reproductive 12 32, 33
Prostate gland 11
Testis 1
Skin 25 26, 34, 35
Endothelial cells 8
Epidermis 5
Keratinocyte 8
Skin 4
Total 427
The total number of biological samples being tested for each broad tissue category and its
corresponding subtissues is shown. Each of the 35 independent studies are listed in
numerical code next to the tissue categories for which they contributed data. See
Supplementary Table S1 for the complete reference corresponding to each code number.
For additional details, see Zheng-Bradley et al (2010).
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nonrandom association. The statistical significance of the
relationship was determined by simulated resampling of the data
to determine the distribution of the number of ‘A’s expected to be
assigned to the susceptible group under the null hypothesis. A total
of 10 000 trials were run and each trial involved cycling through
each of the TSGs (or POGs) in turn and taking a random sample of
size 1 or 2 (corresponding to the number of susceptible tissues for
that gene) from the observed distribution of letter groupings for
that gene. The number of ‘A’s chosen across all TSGs (or POGs)
was the score for that trial. The statistical significance of the
observed score was evaluated based on its position relative to the
null distribution.
Tests of lab effect. We examined the effect of using data from
different laboratories, as these effects are known to be strong
(Zilliox and Irizarry, 2007). Most labs tested only one tissue type,
and hence to avoid subtissue variation we only compared labs that
used the same subtissue type to represent that tissue. The resulting
data set was analysed using a nested ANOVA model (Model:
Expression¼ SubtissueþGeneþ Lab(Subtissue)þGene Subtissueþ
Gene Lab(Subtissue)), with Gene and Subtissue as fixed effects,
and Lab as a random effect. Of interest is the Gene
Lab(Subtissue) interaction where the null expectation is that the
ordering of expression across genes is constant for a given
subtissue. We also calculated the (Pearson) correlation for gene
expression levels both within and between labs. Within labs the
multiple correlation coefficients were averaged using the Fisher’s
z-transform (z¼ (1/2)ln[(1þ r)/(1 r)]), and between labs the
correlation was based on the average expression levels of each lab.
RESULTS
We identified 36 genes that had both hereditary and somatic
mutations linked to cancer, of which 28 were represented by the
probe sets within the expression array. Of these 36 genes, 23
(15 TSGs and 8 POGs) satisfied our criteria for a high-risk familial
effect, with each affecting a single susceptible tissue, with the
exception of PRKAR1A, a TSG that defined two susceptible tissues
(Table 2). Within this group, it was possible to identify susceptible
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Figure 1. The results of the Kruskal–Wallis multiple comparison test are diagrammed for the ATM tumour suppressor gene for its initial test
based on (A) tissue category and (B) the final test using the susceptible subtissue. The figure shows the significance categories (A, AB, and so on)
separating the samples. In the subtissue test, the susceptible tissue category (Immune System) was divided into a susceptible subtissue (lymph
node) and a nonsusceptible subtissue (two subtissues) grouping (see Table 1).
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vs nonsusceptible subtissues within the susceptible tissue category
in 11 TSGs and 2 POGs (Table 2).
Analysis of the average expression of the 15 TSGs and 8 POGs
showed that both groups had significantly higher expression in
susceptible tissue categories, where mutations result in familial
cancer, relative to nonsusceptible tissue categories. The mean log2
expression levels (±1 s.e.) of TSGs in susceptible and nonsuscep-
tible tissue were 0.368±0.254 and  0.130±0.082, respectively,
and in POGs they were 2.24±1.06 and 0.225±0.209, respectively
(Table 2) (Wilcoxon signed rank test: TSGs, V¼ 89, P¼ 0.05,
d.f.¼ 14; POGs, V¼ 35, P¼ 0.008, d.f.¼ 7). This reflected the
finding that 10 of 15 TSGs and 7 of 8 POGs had a higher
expression level in the susceptible tissue categories relative to the
mean of the nonsusceptible tissue categories (Table 2). The same
trend was also found when the susceptible tissue was more
narrowly defined as a subtissue (Wilcoxon signed rank test: TSGs,
V¼ 91, P¼ 0.04, d.f.¼ 14; POGs, V¼ 33, P¼ 0.02, d.f.¼ 7), again
with 10 of 15 TSGs and 7 of 8 POGs having a higher expression
level in the susceptible subtissue relative to the mean of the
nonsusceptible tissues (Table 2).
We next examined the more stringent hypothesis that in its
susceptible tissue or subtissue the expression level of a TSG or POG
is in the statistically most highly expressed tissue (or group of
tissues) for that gene. We first established that there was highly
significant differences in expression among tissues for all 23 genes
(Kruskal–Wallis test; Po0.01 in all cases, after Bonferroni
correction; see Table 2). A posteriori testing to assign a significance
category to each susceptible tissue showed that 33% (5 out of 15) of
TSGs and 63% (5 out of 8) of POGs were most highly expressed in
their susceptible tissue (Table 2). Data resampling tests identified
these patterns to be significant for both TSGs (P¼ 0.02) and POGs
(P¼ 0.0003). The pattern for TSGs became much stronger when
we refined the analysis using, where possible, expression data from
susceptible subtissue rather than from the broad tissue category. Of
the 11 TSGs where a susceptible subtissue was identified, 4 out of
the 8 that were not characterised by significance category ‘A’ in the
initial tissue-level analysis moved into significance category ‘A’ in
the subtissue analysis. The 3 TSGs significant at the tissue category
level remained so in the subtissue analysis (Table 2), so that 9 out
of 15 TSGs (60%; P¼ 0.0001) had their significantly highest
expression in their susceptible tissue (Figure 2A). There was no
difference in the number of ‘A’s between the subtissue and the
broad tissue category score for POGs (Table 2), and hence their
significance was unchanged (P¼ 0.0003). The overall pattern in
POGs is shown in Figure 2B.
We examined whether using data from different laboratories
added significant variation within our tissue groupings using the
cases where it was possible to test for heterogeneity in the ranking
of the expression values of all genes within the same subtissue.
There were six types of subtissue that were used in more than one
lab, with two or three labs per subtissue (Table 3). With lab nested
within subtissue, ANOVA revealed a highly significant Gene by
Lab (Subtissue) interaction (Po0.001; Table 3), indicating that, for
at least some genes, the ranking of the expression levels across
subtissues varied among labs. This laboratory effect would lessen
the chance of the data revealing a consistent pattern.
Despite this heterogeneity, the correlation in gene expression
across labs was generally quite high. Of the 10 possible pairwise
correlations, 5 explained 450% of the variance in the ranking
(i.e. r240.5), whereas 4 explained o33% variance (Table 3).
Another potential source of variation is between replicate
samples within labs. Using the same set of labs, the correlation in
the gene expression values within labs was the same, averaging
0.705 (vs 0.704 between labs; Table 3), with all values explaining
433% of the variance (and 5 out of 9 explaining 450% of the
variance). However, it is clear that the consistency of replication
within labs is relatively poor.
DISCUSSION
We examined the expression levels of 15 TSGs and 8 POGs
implicated in a high risk of familial cancer and found that a gene’s
highest expression was typically found in the tissue susceptible to
the cancer with which it was associated. Specifically, the overall
expression level was generally higher in susceptible tissue
(or subtissue) compared with the average of nonsusceptible tissue
for both TSGs (10 out of 15 TSGs, Po0.05) and POGs (7 out of
8 POGs, Po0.05) and, more importantly, that gene expression in
the susceptible tissue (or subtissue) was within the highest
expression group observed in 9 out of 15 TSGs (Po0.001) and
in 5 out of 8 POGs (Po0.001). Despite the high level of variability
in the data (see below), 3 TSGs and 3 POGs showed a level of
expression significantly higher in their susceptible tissue
(or subtissue) than in all 11 (or 12) other types (see Table 2).
The remainder showed high expression in their susceptible tissue
(or subtissue) that could not be statistically distinguished from
levels in some other tissues; however, our statistical testing
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(via data resampling) incorporated this ambiguity in establishing
the highly significant relationship between high expression and the
susceptible tissue.
This relationship was predicted by the hypothesis of Weinberg
(1988; Horowitz et al, 1990) that TSGs have been evolutionarily
recruited in the susceptible tissues to suppress cancer and that
this has occurred via upregulation of the expression of different
genes in different tissues. This is a basic assumption of the model
of Nunney (1999) for the evolution of cancer suppression: if a
given cancer results in a significant loss of fitness, then natural
selection will act on any genetic variation for tissue-specific
expression of TSGs and POGs that results in a decrease in the
occurrence of that cancer during the pre-reproductive and
reproductive period.
Proto-oncogenes were found to show the same pattern as TSGs.
This result could be due to POGs being recruited as additional
cancer suppressors in a manner analogous to TSGs. This would
require that each added POG adds one more necessary tissue-
specific signalling pathway and hence one more ‘hit’ in the
progression of multistage carcinogenesis. An alternative possibility
is that POGs generally have constitutively higher expression in the
tissues in which they have a critical role in tissue development and
maintenance (Sharma and Sen, 2013). If so, hereditary cancers
arising from mutations in a specific POG occur because the tissue
is especially sensitive to growth signals sent by that POG, or
because such mutations have a bigger effect of perturbing some
other potentially oncogenic cell function than mutations in a POG
that is expressed at lower levels. The link between high expression
and an important role in cell signalling is appealing, and may be a
very general pattern; however understanding the potential role
of POGs in the evolution of cancer suppression requires a
comparative approach to determine whether larger, longer-lived
organisms tend to have additional layers of highly expressed POGs
associated with a given tissue.
A previous study (Lage et al, 2008) failed to find a consistent
relationship between the expression of TSGs and POGs in
susceptible relative to nonsusceptible tissues. They did find a trend
towards overexpression of POGs in susceptible tissues consistent
with our results; however, they also found a trend for the
underexpression of TSGs in susceptible tissues. This difference is
likely because of differences in methodology. For each gene–disease
combination, the authors ranked the tissues by their degree
of susceptibility based upon the number of times a tissue was
co-mentioned in the PubMed literature with a disease of the given
gene. The most highly mentioned 25 tissues were considered as the
susceptible tissues for the given disease–gene combination in their
statistical test. The use of 25 susceptible tissues for a given disease–
gene combination is expected to mask the pattern that we were
looking for: the evolutionary recruitment of cancer suppression in
a very tissue-specific manner.
Our finding that the highest level of expression of a TSG or
a POG generally occurs in the tissue susceptible to the oncogenic
effects of that gene was highly statistically significant, but it was only
established for 14 of the 23 genes examined. However, it is likely that
our results are conservative given a range of biological and
experimental factors that could act to mask the relationship between
gene expression and cancer suppression activity. A number of
experimental factors can cause unpredictable variation in the
Table 3. Variation in gene expression levels within and between laboratories testing the same subtissue
Tissue category Subtissue Lab ID Sample size
Within-lab
correlation (r)
Between-lab
correlation (r)
Brainþnerve Caudate nucleus E-AFMX-6 29 0.715 0.732
GSE3790 1 NA
Heartþmuscle Heart GSE2240 23 0.722 0.880
GSE974 13 0.606
Heartþmuscle Smooth muscle E-MEXP-569 8 0.749 0.570
E-MEXP-66 1 NA
Endocrine organs Thymocyte E-MEXP-337 13 0.623 0.853
GSE1460 1 NA
Brainþnerve Brain GSE5392 23 0.582 0.662
E-LGCL-5 15 0.679 0.301
E-TABM-145 1 NA 0.598
Heartþmuscle Skeletal muscle GSE3307 9 0.797 0.822
GSE6011 7 0.803 0.793
GSE1786 1 NA 0.449
Expression¼ subtissueþgeneþ lab(subtissue)þ subtissuegeneþ lab(subtissue)gene
Effect d.f. SS F-value P-value
Subtissue 5 155.5 6.97 0.003
Gene 22 1003.7 11.86 o0.001
Lab(subtissue) 8 22.8 1.1 0.362
Subtissuegene 110 2510.6 6.14 o0.001
Lab(subtissue)gene 176 554.2 4.18 o0.001
Error 3303 2489.0
The subtissues and their corresponding laboratories (represented by an ArrayExpress experiment ID) are given along with the number of tissue samples that were tested in each lab. For each
lab (with sample size41) an average within-lab correlation was calculated using the expression values across all 23 genes in each sample. For each subtissue, the pairwise correlation between
all labs is given (in the order lab 1 vs 2, 1 vs 3, and 2 vs 3) using the mean expression values across all 23 genes for each lab. The analysis of variance (ANOVA) model and results of the data
analysis are shown at the bottom of the table.
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measures of gene expression. One important source of variation in
expression that our study has highlighted is the precise nature of the
tissue samples. The results of subtissue tests showed that in eight
tests on TSGs where the susceptible tissue was not in the most highly
expressed group, the outcome was reversed for four of the TSGs
when the susceptible subtissue was used (Table 2). This result shows
that reliable results can only be obtained when the specific cell
type(s) that are susceptible to the cancer are examined.
Other important sources of experimental variation acting to
mask general patterns were between-sample (within-lab) varia-
tion and between-lab variation. Within labs using the same
subtissue, the average correlation in the expression of the 23
genes was r¼ 0.705. This leaves 50% of the variance unexplained
because of between-sample effects. When all within-lab expres-
sion values were averaged to minimise the between-sample
variance and these averages were compared between labs, the
correlation was not improved (r¼ 0.704), highlighting substantial
between-lab variation. This high level of between-lab variation
(vs within-lab, between sample variation) was substantiated using
ANOVA that revealed a highly significant lab(subtissue) gene
interaction (Po0.001; see Table 3). The same Affymetrix array
was used by all labs and hence this was not the source of the
variation. Many factors could contribute to both the between-
sample and between-lab variation including the nature and
physiological state of the patients sampled (gender, age, ethnicity,
general health).
It may be possible to control for many of these factors in future
studies by standardising tissue collection protocols, and by using
either protein levels directly or higher quality gene expression
data such as RNAseq. However, other biological factors may still
act to mask the association between expression and tissue
susceptibility. For example, some of these genes may only act as
critical cancer suppressors, and thus be highly expressed, during
certain periods of development. This possibility has been
proposed (but not supported) in the relationship between the
RB1 gene and retinoblastoma (Lee et al, 1988). In our study, two
DNA-repair TSGs, MSH2 and BRCA1, both of which predispose
to ovarian cancer, were found to have low expression in the
ovaries, but extremely high expression in testes tissue. As ovarian
tissues stop dividing before adulthood, but adult testes tissues
continue to proliferate, the expression of these genes in ovarian
tissues may be highest during early development. The small
sample size of pre-adult tissues in our data set precluded the
testing of this hypothesis. It would be useful to include tissue
from different developmental stages (e.g., infant, child, adult) in
future analyses. Alternatively, the failure to find elevated
expression in the ovaries may be because of choosing an
inappropriate susceptible tissue, as many high-grade serous
ovarian tumours have been found to originate in the fallopian
tube (Kurman and Shih, 2010).
In conclusion, our findings support the hypothesis that a high
level of expression is a marker of oncogenic importance in both
TSGs and POGs, as predicted under the model of Nunney (1999)
for the evolution of cancer suppression. This approach has
potential clinical applications. First, cancer-related genes showing
unusually high expression in normal tissue can be examined
further for a possible role in the sporadic cancers of that tissue.
Second, the finding of high expression of a known TSG or POG in
a particular cell type is a potentially useful tool for identifying
candidate genes in our search for causes of familial cancers.
Third, high expression can be used to determine the specific cell
type involved in cancers that have unknown origin and yet the
gene is known (such as rhabdoid tumours and SMARCB1). In
addition, beyond the basic task of linking genes to cancers,
mimicking or generating the signals from these genes may
ultimately provide methods of cancer prevention for the
susceptible tissues.
ACKNOWLEDGEMENTS
We thank Carlo Maley and two anonymous reviewers for their
valuable revisions. We also thank Sonia Peterson, Sasha Prokuda,
Syed Ahmed and Derek O’Meara for their helpful comments on
the manuscript.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A,
Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J,
Pandolfi PP (2010) Subtle variations in Pten dose determine cancer
susceptibility. Nat Genet 42(5): 454–458.
Berger AH, Knudson AG, Pandolfi PP (2011) A continuum model for tumour
suppression. Nature 476(7359): 163–169.
Bignold LP (2004) The cell-type-specificity of inherited predispositions to
tumours: review and hypothesis. Cancer Lett 216(2): 127–146.
Brown MA, Solomon E (1997) Studies on inherited cancers: outcomes and
challenges of 25 years. Trends Genet 13(5): 202–206.
Bunz F (2008) Principles of Cancer Genetics. Springer: New York.
Elledge SJ, Amon A (2002) The BRCA1 suppressor hypothesis: an explanation
for the tissue-specific tumor development in BRCA1 patients. Cancer Cell
1(2): 129–132.
Eng C, Ponder BA (1993) The role of gene mutations in the genesis of familial
cancers. FASEB J 7(10): 910–919.
Fearon ER (1997) Human cancer syndromes: clues to the origin and nature of
cancer. Science 278(5340): 1043–1050.
Friedenson B (2010) A theory that explains the tissue specificity of
BRCA1/2 related and other hereditary cancers. J Med Med Sci 1(8):
372–384.
Friend SH, Bernards RA, Rogelj S, Weinberg RA, Rapaport JM, Albert DM,
Dryja TP (1986) A human DNA segment with properties of the gene that
predisposes to retinoblastoma and osteosarcoma. Nature 323(6089):
643–646.
Fung YK, Murphree AL, T’ang A, Qian J, Hinrichs SH, Benedict WF (1987)
Structural evidence for the authenticity of the human retinoblastoma gene.
Science 236(4809): 1657–1661.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N,
Stratton MR (2004) A census of human cancer genes. Nat Rev Cancer 4(3):
177–183.
Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S,
Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C,
Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software
development for computational biology and bioinformatics. Genome Biol
5(10): R80.
Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005)
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of
human genes and genetic disorders. Nucleic Acids Res 33(Suppl 1): D514–
D517.
Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ,
Minna JD, Dryja TP, Weinberg RA (1990) Frequent inactivation of the
retinoblastoma anti-oncogene is restricted to a subset of human tumor
cells. Proc Natl Acad Sci USA 87(7): 2775–2779.
Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial
ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):
433–443.
Knudson AG (1989) Hereditary cancers: clues to mechanisms of carcinogenesis.
Br J Cancer 59: 661–666.
Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma.
Proc Natl Acad Sci USA 68(4): 820–823.
Lage K, Hansen NT, Karlberg EO, Eklund AC, Roque FS, Donahoe PK,
Szallasi Z, Jensen TS, Brunak S (2008) A large-scale analysis of tissue-
specific pathology and gene expression of human disease genes and
complexes. Proc Natl Acad Sci USA 105(52): 20870–20875.
BRITISH JOURNAL OF CANCER Tissue-specific expression of cancer-related genes
352 www.bjcancer.com |DOI:10.1038/bjc.2015.205
Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH (1988) Inactivation of
the retinoblastoma susceptibility gene in human breast cancers. Science
241(4862): 218–221.
Lindor NM, McMaster ML, Lindor CJ, Greene MH (2008) Concise handbook
of familial cancer susceptibility syndromes. J Natl Cancer Inst Monogr 38:
3–93.
Little CH (1923) The relation of genetics to the problems of cancer research.
Harvey Lect 17: 65–88.
Marsh DJ, Dahia PL, Coulon V, Zheng Z, Dorion-Bonnet F, Call KM, Little R,
Lin AY, Eeles RA, Goldstein AM, Hodgson SV, Richardson A, Robinson
BG, Weber HC, Longy M, Eng C (1998) Allelic imbalance, including
deletion of PTEN/MMAC1, at the Cowden disease locus on 10q22-23, in
hamartomas from patients with Cowden syndrome and germline PTEN
mutation. Genes Chromosomes Cancer 21(1): 61–69.
Monteiro AN (2003) BRCA1: the enigma of tissue-specific tumor development.
Trends Genet 19(6): 312–315.
Morgan TH (1922) Some Possible Bearings of Genetics on Pathology. New Era
Printing Co: Lancaster, PA.
Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR,
Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A,
Ponder BAJ (1993) Germ-line mutations of the RET proto-oncogene in
multiple endocrine neoplasia type 2A. Nature 363(6428): 458–460.
Nunney L (1999) Lineage selection and the evolution of multistage carcinogenesis.
Proc Biol Sci 266(1418): 493–498.
Nunney L (2013) The real war on cancer: the evolutionary dynamics of cancer
suppression. Evol Appl 6(1): 11–19.
Peto R (1977) Epidemiology, multistage models, and short-term mutagenicity
tests. In The Origins of Human Cancer, Hiatt HH, Watson JD, Winsten JA
(eds) Vol. 4: 1403–1428. Cold Spring Harbor Conferences on Cell
Proliferation. Cold Spring Harbor Laboratory: New York.
Plevova´ P, Sedla´kova´ E, Zapletalova´ J, Krˇepelova´ A, Sky´palova´ P, Kola´rˇ Z
(2005) Expression of the hMLH1 and hMSH2 proteins in normal tissues:
relationship to cancer predisposition in hereditary non-polyposis colon
cancer. Virchows Arch 446(2): 112–119.
R Development Core Team (2008) R: A Language and Environment for
Statistical Computing. R Foundation for Statistical Computing: Vienna,
Austria, ISBN 2-900051-07-0, URL http://www.R-project.org.
Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ,
Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L,
Eisner MP, Reichman M, Edwards BK (2008) SEER Cancer Statistics
Review 1975-2005. National Cancer Institute: Bethesda, MD.
Seluanov A, Chen Z, Hine C, Sasahara TH, Ribeiro AA, Catania KC,
Presgraves DC, Gorbunova V (2007) Telomerase activity coevolves with
body mass not lifespan. Aging Cell 6(1): 45–52.
Seluanov A, Hine C, Azpurua J, Feigenson M, Bozzella M, Mao Z, Catania KC,
Gorbunova V (2009) Hypersensitivity to contact inhibition provides a clue
to cancer resistance of naked mole-rat. Proc Natl Acad Sci USA 106(46):
19352–19357.
Sharma A, Sen JM (2013) Molecular basis for the tissue specificity of b-catenin
oncogenesis. Oncogene 32(15): 1901–1909.
Silver DP, Livingston DM (2012) Mechanisms of BRCA1 tumor suppression.
Cancer Discov 2(8): 679–684.
Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA,
Fletcher CD, Knight JC, Fung YK, Reeves BR (1989) Structural alterations
of the RB1 gene in human soft tissue tumours. Br J Cancer 60(2): 202.
Varley JM, Evans DG, Birch JM (1997) Li-Fraumeni syndrome–a molecular
and clinical review. Br J Cancer 76(1): 1.
Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1
and BRCA2. Cell 108(2): 171–182.
Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control.
Nat Med 10(8): 789–799.
Weinberg RA (1988) Finding the anti-oncogene. Sci Am 259(3): 44–51.
Weinberg RA (1989) The molecular basis of retinoblastomas. Ciba Found
Symp 142: 99–105.
Weinberg RA (2007) The Biology of Cancer Vol. 1Garland Science: New York.
Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast
and ovarian cancer. Hum Mol Genet 10(7): 705–713.
Zheng-Bradley X, Rung J, Parkinson H, Brazma A (2010) Large scale comparison of
global gene expression patterns in human and mouse. Genome Biol 11(12): R124.
Zilliox MJ, Irizarry RA (2007) A gene expression bar code for microarray data.
Nat Methods 4(11): 911–913.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Tissue-specific expression of cancer-related genes BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.205 353
